

31 July 2014

## TENDER RESULTS

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the **12<sup>th</sup> of the month prior to the date of subsidy change**. More information and NOPC forms can be found on our website – <http://www.pharmac.health.nz/medicines/how-medicines-are-funded/new-funding-applications/pharmaceutical-product-specifications-the-change-process>

Where a product does not have a current Pharmacode, suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand before the 12<sup>th</sup> of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

**2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017**

### Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

**Amendment to June Tender notification (Sole Subsidised Supply date) in bold and strike through**

1. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

A707041 - qA25123

Chemical Name	Presentation; Pack size and type	Current subsidy and (price)	New subsidy and price	Sole supply brand (Supplier)	Date of listing/subsidy change for tender winning brand	Date of reference pricing of other listed brands	Sole Subsidised Supply date (and delisting of other listed brands)	Brand (Supplier) affected by reference pricing and delisting
Tar with triethanolamine lauryl sulphate and fluorescein	Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium; 500 ml, bottle	\$3.05 per 500 ml	\$3.36 per 500 ml	Pinetarsol (Douglas)	1 October 2014	n/a	1 March <del>2014</del> <b>2015</b>	Pinetarsol (1,000 ml pack size) (Douglas)

## Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

### Amendment to June Tender notification (pack size) in bold

2. Tenders awarded to listed pharmaceuticals where only the current brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of price change	Hospital Supply Status date
Morphine sulphate	Inj 1 mg per ml, 10 ml syringe; <b>10 syringes</b>	\$39.50	\$45.00	Biomed (Biomed)	1%	1 August 2014	1 October 2014
Morphine sulphate	Inj 1 mg per ml, 50 ml syringe; <b>10 syringes</b>	\$79.50	\$87.50	Biomed (Biomed)	1%	1 August 2014	1 October 2014
Morphine sulphate	Inj 1 mg per ml, 100 ml bag; <b>10 bags</b>	\$165.00	\$185.00	Biomed (Biomed)	1%	1 August 2014	1 October 2014

**2013/14 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2017**

**Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

3. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

<b>Chemical Name</b>	<b>Presentation; Pack size and type</b>	<b>Current subsidy and (price)</b>	<b>New subsidy and price</b>	<b>Sole supply brand (Supplier)</b>	<b>Date of listing/subsidy change for tender winning brand</b>	<b>Date of reference pricing of other listed brands</b>	<b>Sole Subsidised Supply date (and delisting of other listed brands)</b>	<b>Brand (Supplier) affected by reference pricing and delisting</b>
Docosate sodium	Tab 50 mg; 100 tablet, bottle	\$2.57	\$2.31	Coloxyl (Aspen Pharma)	1 November 2014	1 January 2015	1 April 2015	Laxofast 50 (Actavis)
Docosate sodium	Tab 120 mg; 100 tablet, bottle	\$3.48	\$3.13	Coloxyl (Aspen Pharma)	1 November 2014	1 January 2015	1 April 2015	Laxofast 120 (Actavis)
Finasteride	Tab 5 mg; 28 tablet, blister pack	\$5.10 per 30 tablets	\$1.95	Finpro (Dr Reddy's)	1 October 2014	1 December 2014	1 March 2015	Rex Medical (Rex Medical)

## Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

4. Tenders awarded to pharmaceuticals where at least one other brand or pack size is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Current pack price	New pack price	Hospital Supply Brand (Supplier)	DV Limit	Date of listing/price change for tender winning brand	Hospital Supply Status date (and delisting of other listed brands)	Brand (Supplier) to be delisted
Docetaxel	Inj 20 mg; 1 vial	\$48.75	\$13.70	DBL Docetaxel (Hospira)	1%	1 October 2014	1 December 2014	Docetaxel Sandoz (Novartis)
Docetaxel	Inj 80 mg; 1 vial	\$195.00	\$29.99	DBL Docetaxel (Hospira)	1%	1 October 2014	1 December 2014	Docetaxel Sandoz (Novartis)
Docusate sodium	Tab 50 mg; 100 tablet, bottle	\$2.57	\$2.31	Coloxyl (Aspen Pharma)	1%	1 November 2014	1 January 2015	Laxofast 50 (Actavis)
Docusate sodium	Tab 120 mg; 100 tablet, bottle	\$3.48	\$3.13	Coloxyl (Aspen Pharma)	1%	1 November 2014	1 January 2015	Laxofast 120 (Actavis)
Finasteride	Tab 5 mg; 28 tablet, blister pack	\$5.10 per 30 tablets	\$1.95	Finpro (Dr Reddy's)	1%	1 October 2014	1 December 2014	Rex Medical (Rex Medical)

The price and subsidy of docetaxel (PCT – Retail Pharmacy Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 October 2014. The subsidy for docetaxel inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will change from \$2.63 per 1 mg to \$0.61 per 1 mg from 1 October 2014.

5. Tenders awarded to pharmaceuticals where no brand is listed.

The decisions were as follows:

Chemical Name	Presentation; Pack size and type	Pack price	Hospital Supply Brand (Supplier)	DV Limit	Listing date	Hospital Supply Status date
Ticarcillin with clavulanic acid	Inj ticarcillin 3 g with clavulanic acid 0.1 mg vial; 1 vial	\$22.00	Timentin (GSK)	1%	1 December 2014	1 February 2015

## Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2011/12 Invitation to Tender, dated 2 November 2011, the 2012/13 Invitation to Tender, dated 31 October 2012, and the 2013/14 Invitation to Tender, dated 07 November 2013:

### 2011/12 Invitation to Tender

Chemical Name	Line Item
<b>Bupivacaine hydrochloride</b>	Inj 0.5%, 10 ml
<b>Oxycodone hydrochloride</b>	Cap 5 mg

Chemical Name	Line Item
<b>Oxycodone hydrochloride</b>	Cap 10 mg
<b>Oxycodone hydrochloride</b>	Cap 20 mg

### 2012/13 Invitation to Tender

Chemical Name	Line Item
<b>Beclomethasone Dipropionate</b>	Metered aqueous nasal spray, 50 mcg per dose
<b>Beclomethasone Dipropionate</b>	Metered aqueous nasal spray, 100 mcg per dose
<b>Betamethasone Valerate</b>	Crm 0.1%
<b>Betamethasone Valerate</b>	Lotn 0.1%
<b>Bisacodyl</b>	Tab 5 mg
<b>Budesonide</b>	Metered aqueous nasal spray, 50 mcg per dose
<b>Budesonide</b>	Metered aqueous nasal spray, 100 mcg per dose
<b>Cetomacrogol</b>	Crm BP
<b>Cholecalciferol</b>	Tab 1.25 mg (50,000 iu)
<b>Ciprofloxacin</b>	Inj 2 mg/ml, 100 ml
<b>Co-Trimoxazole</b>	Tab trimethoprim 80 mg and sulphamethoxazole 400 mg

Chemical Name	Line Item
<b>Magnesium</b>	Tab
<b>Methadone hydrochloride</b>	Tab 5 mg
<b>Mupirocin</b>	Oint 2%
<b>Nystatin</b>	Cap 500,000 u
<b>Nystatin</b>	Tab 500,000 u
<b>Pegylated liposomal doxorubicin</b>	Inj 20 mg
<b>Pegylated liposomal doxorubicin</b>	Inj 50 mg
<b>Prednisolone</b>	Oral liq 5 mg per ml
<b>Solifenacin succinate</b>	Tab 10mg
<b>Solifenacin succinate</b>	Tab 5mg
<b>Thalidomide</b>	Cap 50 mg

Chemical Name	Line Item
<b>Docusate Sodium with Sennosides</b>	Tab 50 mg with total sennosides 8 mg
<b>Hydrocortisone with Miconazole</b>	Crm 1% with miconazole nitrate 2%
<b>Lorazepam</b>	Inj 4 mg per ml, 1 ml
<b>Lorazepam</b>	Tab 1 mg
<b>Lorazepam</b>	Tab 2.5 mg

Chemical Name	Line Item
<b>Thalidomide</b>	Cap 100 mg
<b>Valaciclovir</b>	Tab 250 mg
<b>Valaciclovir</b>	Tab 500 mg
<b>Valaciclovir</b>	Tab 1000 mg

*2013/14 Invitation to Tender*

Chemical Name	Line Item
<b>Nitrofurantoin</b>	Tab 50 mg
<b>Nitrofurantoin</b>	Tab 100 mg

Chemical Name	Line Item
<b>Tramadol hydrochloride</b>	Oral drops 100 mg per ml
<b>Tramadol hydrochloride</b>	Tab sustained release 50 mg

PHARMAC has resolved not to award tenders for Hospital Supply Status for the following products listed in the 2013/14 Invitation to Tender, dated 07 November 2013:

Chemical Name	Line Item
<b>Tar with triethanolamine lauryl sulphate and fluorescein</b>	Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium

For products included in the 2012/13 or the 2013/14 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.